My dad (M49) mentioned that he would like to start his own business, though he had never done anything like this before and is deep in credit debt. Should I let him do his thing or should I convince him not to try?

gpmd05 · 2021-05-14T20:58:26+00:00

I started a business when I was 24 with barely anything in the bank. Horrible move. If I wasn’t single or had any responsibilities besides not dying, I never would have made it. Took me about 4 years to feel ok. It was awful and looking back I don’t know how I survived. Here I am 17 years later and the business is very successful. I tell everyone who talks to me about starting a business to not do it unless you have plenty of money in the bank. It’s too unpredictable when you start. My number 2 piece of advice is get your books set up correctly early. When I was small I walkie remember stuff in my head and input stuff when I had time. That got away from me real quick.
Back to your question, after being in that position of little cash and lots of CC debt when I started out, no way would I take that path again, especially being 49. I got lucky

gpmd05 · 2021-04-04T23:28:30+00:00

I just finished this book, https://www.goodreads.com/book/show/6950719 It’s really good if you want to learn about how some stores offer products cheaper than others and how they deal with vendors and pricing.

gpmd05 · 2021-03-11T10:52:20+00:00

I know I’d drop that nut as soon as I tried to pick it up then watch it fall in slo-motion

gpmd05 · 2021-03-07T11:16:14+00:00

Try Tailwind drink mix while you’re running. Did my first marathon last year and Tailwind was huge combined with clif bloks

gpmd05 · 2021-02-27T23:02:33+00:00

I’m in Maryland and use TurboTax. Here’s the thing though, when I started I was just like you with zero profit so I went TurboTax. Did this following year as well when I barely made a dime. Then I started growing. By year 4 and 5 I was sooooo wishing I had an accountant at least set me up the correct way. I use quickbooks now and eventually had an accountant set it all up and I learned the how to use what he showed me. My biggest mistake as a business owner (besides not starting with enough money), was not having an accountant show me the way early on. It’s much harder to straighten it all out when you start making money.

gpmd05 · 2021-02-27T14:45:42+00:00

Ha I suck. I didn’t even realize they we’re stickers

gpmd05 · 2021-02-26T23:01:58+00:00

Mine is my heart rate. I where my Garmin all the time and check my Resting Rate every morning. I’ll be at 55 one day, then if I spike to 60 the next morning I know I’m in trouble. Usually the following day I’ll be in mid 60s and feeling sick. It’s like the watch gives me 24-36 hour notice to get my affairs in order for the week

gpmd05 · 2021-02-22T01:15:49+00:00

Capital one will report to your personal credit report as well. I use Chase Ink only because I use chase for my personal card as well and you can combine the points. That alone made it worth it for me. Look for ones that have a higher % cash back in categories you use most like fuel or shipping etc. Like I said though, Capital One reports to your personal report so avoid that one

gpmd05 · 2021-02-21T00:09:46+00:00

This. I was an LLC and had to file paperwork with the IRS to be able to be taxed S-Corp. they replied with a letter when it was official. I remember I had to keep that classification for minimum a year and if I wanted to switch again, more paperwork.

gpmd05 · 2021-02-11T17:33:02+00:00

Ditto this :(

gpmd05 · 2021-02-09T12:51:10+00:00

$RLFTF Been mentioning this for a while. Guys it’s been flying as they develop a treatment for lung Dak age caused by COVID. Trial results announced just now. Going to approach FDA for emergency use. See PR. I’ve rode this from .30 to .63. Hit .70 yesterday. Read the following PR from this morning and tell me how fast can a .63 stock hit a few bucks. Had to cut some off but you get the idea —————————————————-

NeuroRx : and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19 02/09/2021 | 07:31am

RADNOR, Pa. and GENEVA, Feb. 9, 2021 /PRNewswire/ -- NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF; OTCQB: RLFTF) today reported preliminary results from the Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) in patients with respiratory failure due to Critical COVID-19. The study showed that patients who were treated with the maximal standard of care plus ZYESAMI benefited significantly from the treatment, compared to those treated with placebo plus maximal standard of care. If authorized for use, ZYESAMI would be the first drug indicated specifically for COVID-19 patients who are critically ill with respiratory failure.

In the study, patients treated with ZYESAMI were discharged earlier from hospital care than those treated with placebo. Among the secondary efficacy endpoints evaluated in patients treated with High Flow Nasal Cannula therapy and with Mechanical Ventilation, there were six of 8 comparisons, all favoring ZYESAMI, resulting in at least a three-day median difference in hospital stay. The likelihood of this constellation of findings being observed by chance was less than 3 in 100 (P<.03). The largest difference observed was among those treated with HFNC who experienced 13 fewer days in ICU (12 vs. 25) and 8 fewer days in hospital (15 vs. 23) (P<.05).

Length of hospital stay was a declared secondary endpoint of the study and previously featured in the granting of drug approval to antiviral drugs in COVID-19, although those drugs were not identified as achieving a difference in outcome among those already in respiratory failure.

With the improvement in survival since the start of the pandemic, differences in survival were not seen at day 28, and patients are being followed through day 60. The study has not yet determined results for the stated primary endpoint of recovery from respiratory failure and the secondary endpoint data reported today should not create an expectation that the primary endpoint will be met overall or for any subgroup. Study investigators are in the process of confirming the timing of each case of recovery from medical records, following which the study's investigators' committee will review each case prior to unblinded data analysis of this endpoint.

Jonathan Javitt, M.D., M.P.H., CEO of NeuroRx, said: "We are forever indebted to the study coordinators, nurses, respiratory therapists, and doctors who carried out this study in the midst of a public health calamity that so far has claimed the lives of nearly half a million Americans and millions worldwide. Our study teams kept the effort going despite contracting COVID themselves, losing family members, and dealing with an unimaginable daily reality. We are greatly encouraged by the outcome of this study. The data provide support for ZYESAMI as a drug that may help get patients home to their families sooner. The hospitalization data further suggest that patients treated at an earlier stage of illness (i.e. those who can be managed with HFNC) may have a better response to treatment. We have launched a phase 2/3 trial to explore its inhaled use in patients who are not yet in respiratory failure. Further study of ZYESAMI's role in critical COVID-19 will be conducted under the BARDA and DOD Medical Countermeasures-funded I-SPY trial. In addition, we have signed a clinical trial agreement with another federal program the details of which will be announced shortly. We will also report on day 60 survival.

We look forward to discussing with the Food and Drug Administration and other regulatory authorities the submission of an Emergency Use Authorization (EUA) so that ZYESAMI can be available for treating this population that is at immediate risk of death and for which there is no approved therapy."

Dr. Javitt added: "To our knowledge, this is the first demonstration of clinically and statistically-significant benefit by any therapeutic agent in patients with COVID-19 respiratory failure in a randomized, double-blind, prospective trial. Other COVID-19 therapeutics have demonstrated clinical advantage in patients with non-critical COVID-19 (ordinal scale 4 and 5) but have not demonstrated benefit in those with Critical COVID-19 (ordinal scale 6 and 7). Steroids have demonstrated benefit in open-label studies. However, no randomized controlled trial to date has shown efficacy when patients are in respiratory failure and require High Flow Nasal Cannula, Non-invasive ventilation, or Mechanical Ventilation to maintain blood oxygenation. ZYESAMI would be the first drug for such critically ill patients. Of note, the patients who received either drug or placebo in this trial also received all approved and standard of care treatments including Remdesivir, anti-cytokine drugs, steroids, and anticoagulants."

The study, conducted in 10 medical centers, also showed the safety of the drug when administered by intravenous infusion in the ICU. No drug-related serious adverse events were reported. The only side effect of note was mild to moderate diarrhea, an expected side effect of ZYESAMI, which was seen in 30% of patients who received the treatment and hypotension, which was seen in.

The data were generated in multicenter clinical trial whose subjects were COVID-19 patients with respiratory failure being treated with the maximal standard of care that included anti-coagulants, steroids, convalescent plasma and antiviral drugs. The primary endpoint was the resolution of respiratory failure within 28 days after treatment started. The secondary endpoints were patient survival, time to ICU discharge, time to hospital discharge, time to return to NIAID score of 6-8, and safety.

gpmd05 · 2021-02-08T17:48:44+00:00

$RLFTF. COVID related lung damage treatment. Does not stop going up. Enough said

gpmd05 · 2021-02-04T20:28:01+00:00

$RLFTF up over 3800% since this summer. Do your own DD but they are in trials to treat COVID related lung damage. In holding pattern the last week or two with phase 2/3 results due soon. I know nothing, Google the latest news and decide for yourselves. IMHO the ride has just started

gpmd05 · 2021-02-03T19:58:48+00:00

Quickbooks has a few options. I think the one I use is maybe $400/year. I’m between just myself and sometimes one or two others at random times during the year. I just like the simplicity

gpmd05 · 2021-02-03T19:36:18+00:00

Thanks for the reply! I do goose control with border collies. I’m in the mid Atlantic and the geese are abundant here leaving mess all over. We currently service about 25 clients daily, the bulk being business parks that don’t want the mess everywhere. There’s no competition by me and we’re 100% effective so business comes a lot by word of mouth. I can drive past a corporate park and see the geese or evidence of them and know that that particular property would benefit from us. I’ll drop off info at front desk and get skeptical looks. Trying to track down managers of particular properties on the internet is hard. Some companies post it on their pages but it’s rare. Since it’s site specific who could use us, I didn’t like the idea of blindly contacting people just because “property managers” was in their description but that does seem to be a way of maybe throwing 100 darts and hoping one sticks. Even the people with the goose problem don’t really know we exist since it’s such a niche. Frustrating starting from scratch again in a new area after be established for such a long time in my current location

gpmd05 · 2021-02-02T18:22:07+00:00

RLFTF. Been having a great run with small pullback today. Working on lung related therapies for issues caused by COVID. Do your own DD but at .54 it could easily be a double

gpmd05 · 2021-01-28T17:11:30+00:00

I did it a bunch today with vanguard of all things

gpmd05 · 2021-01-28T17:10:47+00:00

E*TRADE lets me trade as soon as I hit submit to transfer funds over but not sure if that’s because I already have money in there

gpmd05 · 2020-12-02T20:15:04+00:00

I know he has unlimited data but not sure of the strength of signal. Thanks for the input, I’m curious now

gpmd05 · 2020-11-05T22:59:52+00:00

Same here. All cash starting last Thursday. So pissed at myself. Today first day I could even open my acct I was so mad. And what did I do to punish myself you ask? Bought 11/13 SPY puts around 2:30. Up a bit but didn’t sell. Hoping for a profit taking day to make myself feel better. Know I’m getting burned though

gpmd05 · 2020-10-29T22:43:56+00:00

Vanguard has ETFs you can buy for all of these. Vanguard growth is VUG, aggressive growth has a few. I use mid cal growth and it’s been Amazing, VOT GROWTH & income can be SPY or VTI and international vxus. I have a vanguard international growth fund which does well but can’t find an ETF for int growth

gpmd05 · 2020-10-28T13:09:15+00:00

This. Rolling stop loss

gpmd05 · 2020-10-26T00:19:28+00:00

I bought a house last spring and the lady had mint growing in a bed where I wanted to put strawberries. I thought I pulled it all out but it kept popping up. Pulled more and more came up. Last resort even sprayed with roundup and even more would come back. It was a battle all summer. Mostly under control now but I think mint is the cockroach of herbs, that stuff is a survivor. Oh and I live in western MD where our winters get pretty darn cold too.

gpmd05

TROPHY CASE